Neogen Corporation Cash and Restricted Cash
Neogen Corporation (NEOG) had Cash and Restricted Cash of $185.50 million as of 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-05-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $185.50M.
- 2026-02-28: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $159.90M.
- 2025-11-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $145.34M.
- 2025-08-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $138.88M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-05-31 | $185.50M 10-K · filed 2026-07-30 | |
| 2026-02-28 | $159.90M 10-Q · filed 2026-04-09 | |
| 2025-11-30 | $145.34M 10-Q · filed 2026-01-08 | |
| 2025-08-31 | $138.88M 10-Q · filed 2025-10-09 | |
| 2025-05-31 | $129.00M 10-K · filed 2026-07-30 | $129.00M 10-K · filed 2025-07-30 |
| 2025-02-28 | $127.70M 10-Q · filed 2026-04-09 | $127.70M 10-Q · filed 2025-04-09 |
| 2024-11-30 | $140.23M 10-Q · filed 2026-01-08 | |
| 2024-08-31 | $120.48M 10-Q · filed 2025-10-09 | |
| 2024-05-31 | $170.60M 10-K · filed 2026-07-30 | $170.61M 10-K · filed 2024-07-30 |
| 2024-02-29 | $161.44M 10-Q · filed 2024-04-09 | |
| 2023-11-30 | $161.44M 10-Q · filed 2025-04-09 | $205.76M 10-Q · filed 2024-01-09 |
| 2023-08-31 | $178.83M 10-Q · filed 2024-10-10 | |
| 2023-05-31 | $163.20M 10-K · filed 2026-07-30 | $163.24M 10-K · filed 2023-08-15 |
| 2023-02-28 | $67.13M 10-Q · filed 2024-04-09 | |
| 2022-11-30 | $100.00M 10-Q · filed 2024-01-09 | |
| 2022-08-31 | $107.10M 10-Q · filed 2023-10-10 | |
| 2022-05-31 | $44.47M 10-K · filed 2025-07-30 | |
| 2022-02-28 | $42.88M 10-Q · filed 2023-04-04 | |
| 2021-11-30 | $51.12M 10-Q · filed 2023-01-09 | |
| 2021-08-31 | $71.28M 10-Q · filed 2022-09-30 | |
| 2021-05-31 | $75.60M 10-K · filed 2024-07-30 | |
| 2020-05-31 | $66.27M 10-K · filed 2023-08-15 | |
| 2019-05-31 | $41.69M 10-K · filed 2022-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |